Future works should focus on developing drugs specifically inhibiting PGF signaling or, ideally, PGF and VEGFA, and on exploring the synergistic effects of combining these drugs with immunotherapy for more effective clinical treatments of bladder cancer. The gene discussed is VEGFA; the disease is urinary bladder carcinoma.